<DOC>
	<DOCNO>NCT00751231</DOCNO>
	<brief_summary>This multi-center , randomize , double-blind , triple-dummy , clopidogrel-controlled study IV oral PRT060128 compare clopidogrel patient undergo non-urgent ( include elective ) PCI . After diagnostic angiography , patient schedule non-urgent PCI randomize clopidogrel one three dose level PRT060128 .</brief_summary>
	<brief_title>A Phase 2 Safety Efficacy Study PRT060128 , Novel Intravenous Oral P2Y12 Inhibitor , Non-Urgent PCI</brief_title>
	<detailed_description>Each patient randomize trial participate approximately 12-24 week , include Screening period 2 week , acute peri-procedural phase , 60-120 day chronic treatment phase . The chronic phase include daily in-hospital assessment 24 Hours Discharge ( whichever come first ) , telephone follow-up Day 7-10 post-Discharge , outpatient follow-up visit Days 30 60-67 , [ Day 90 Day 120 ( treat 120 day ) ] telephone follow-up 7 day follow last dose study drug .</detailed_description>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>The patient schedule undergo nonurgent PCI The patient 18 75 year age ( inclusive ) willing comply protocol Women childbearing potential must negative serum urine pregnancy test within 24 hour dose . All patient must agree use double barrier contraception study least 4 week last dose . The patient legally acceptable representative able read give write informed consent sign informed consent form approve Investigator 's IRB/IEC Estimated measure weight &lt; 55 kg Acute nonSTsegment elevation myocardial infarction ( NSTEMI ) STsegment elevation myocardial infarction ( STEMI ) within 7 day prior PCI Chronic total occlusion unprotected leave main stenting Cardiogenic shock ( systolic blood pressure &lt; 90 mm Hg require vasopressor hemodynamic support ) Uncontrolled hypertension time initial study drug administration define measure systolic blood pressure &gt; 190 mm Hg diastolic blood pressure &gt; 108 mm Hg Planned stag PCI Planned surgery study period Planned GP IIb/IIIa use Patient receive clopidogrel load dose ( â‰¥300 mg ) within 7 day prior randomization ; patient maintenance clopidogrel may enrol The planned administration studyspecified clopidogrel load dose &gt; 12 hour prior PCI Administration thrombolytic agent , fondaparinux , oral anticoagulant ( e.g. , warfarin ) within 7 day prior PCI Estimated creatinine clearance ( e.g . CockcroftGault ) &lt; 45 mL/min Anemia hemoglobin level &lt; 10 g/dL Thrombocytopenia ( platelet count &lt; 100,000/mm3 ) ALT and/or AST &gt; 2.5 x ULN indication clinically significant hepatic dysfunction Facial head trauma within last 30 day Intraocular hemorrhage within last 30 day Gastrointestinal bleeding within last 30 day Active bleeding , history bleed disorder know intracranial vascular malformation History prior ischemic stroke TIA within last 5 year intracranial hemorrhage , neoplasm , arteriovenous malformation Known allergy contraindication component PRT060128 , aspirin , heparin , clopidogrel , glycoprotein IIb/IIIa inhibitor , contrast medium Participation investigational drug study within 30 day prior enrollment . Participation device trial prior enrollment acceptable Prior participation study involve PRT060128 Any condition could interfere , treatment might interfere , conduct study would , opinion Investigator , unacceptably increase patient 's risk participating study . This would include , limited alcoholism , drug dependency abuse , psychiatric disease , epilepsy unexplained blackout</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>PCI</keyword>
	<keyword>percutaneous coronary intervention</keyword>
</DOC>